Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Conditions

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Trial Timeline

Sep 29, 2020 → Jul 22, 2024

NCT ID

NCT04245085

About Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed

Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel + Pemetrexed is a phase 2 stage product being developed by Roche for EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT04245085. Target conditions include EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04245085	Phase 2	Completed	Sep 29, 2020	Jul 22, 2024	EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC